Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 6Other hematologic neoplasm 2Myeloid 2Gynecologic 2Sarcoma 1Other 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 344Rituximab 307Vincristine 159Doxorubicin 156venetoclax 154Specimen Handling 154fludarabine 153Prednisone 151Biopsy 124Magnetic Resonance Spectroscopy 119obinutuzumab 116Lenalidomide 110Dexamethasone 105Cytarabine 98ibrutinib 96Etoposide 92fludarabine phosphate 87Methotrexate 85acalabrutinib 78Bendamustine Hydrochloride 73zanubrutinib 72blinatumomab 64pembrolizumab 62CT-P10 60Gemcitabine 51Nivolumab 45Calcium Dobesilate 45glofitamab 44Mercaptopurine 44prednylidene 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
TIC10 compound × Lymphoid × 1 year × Clear all
NCT02392572 2026-04-14

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
120 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡